LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 235

Search options

  1. Article ; Online: Diagnosis and Pharmacological Management of Microscopic Colitis in Geriatric Care.

    Nielsen, Ole Haagen / Pardi, Darrell S

    Drugs & aging

    2024  Volume 41, Issue 2, Page(s) 113–123

    Abstract: Microscopic colitis, a diagnosis under the umbrella term of inflammatory bowel disease, is a prevalent cause of watery diarrhea, often with symptoms of urgency and bloating, typically observed in older adults aged ≥ 60 years. Its incidence has been ... ...

    Abstract Microscopic colitis, a diagnosis under the umbrella term of inflammatory bowel disease, is a prevalent cause of watery diarrhea, often with symptoms of urgency and bloating, typically observed in older adults aged ≥ 60 years. Its incidence has been reported to exceed those of ulcerative colitis and Crohn's disease in some geographical areas. Although nonpathognomonic endoscopic abnormalities, including changes of the vascular mucosal pattern; mucosal erythema; edema; nodularity; or mucosal defects, e.g., "cat scratches" have been reported, a colonoscopy is typically macroscopically normal. As reliable biomarkers are unavailable, colonoscopy using random biopsies from various parts of the colon is compulsory. Based on the histological examination under a microscope, the disease is divided into collagenous (with a thickened subepithelial collagenous band) and lymphocytic (with intraepithelial lymphocytosis) colitis, although incomplete forms exist. In routine clinical settings, the disease has a high risk of being misdiagnosed as irritable bowel syndrome or even overlooked. Therefore, healthcare providers should be familiar with clinical features and rational management strategies. A 6-8-week oral budesonide treatment course (9 mg/day) is considered the first-line therapy, but patients often experience relapse when discontinued, or might become intolerant, dependent, or even fail to respond. Consequently, other therapeutic options (e.g., bismuth subsalicylate, biologics, loperamide, bile acid sequestrants, and thiopurines) recommended by available guidelines may be prescribed. Herein, clinically meaningful data is provided based on the latest evidence that may aid in reaching a diagnosis and establishing rational therapy in geriatric care to control symptoms and enhance the quality of life for those affected.
    MeSH term(s) Humans ; Aged ; Quality of Life ; Colitis, Microscopic/diagnosis ; Colitis, Microscopic/drug therapy ; Colitis, Microscopic/epidemiology ; Colonoscopy/adverse effects ; Diarrhea ; Colitis, Ulcerative
    Language English
    Publishing date 2024-01-17
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 1075770-3
    ISSN 1179-1969 ; 1170-229X
    ISSN (online) 1179-1969
    ISSN 1170-229X
    DOI 10.1007/s40266-023-01094-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Reply.

    Tome, June / Khanna, Sahil / Pardi, Darrell S

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

    2024  

    Language English
    Publishing date 2024-02-15
    Publishing country United States
    Document type Letter
    ZDB-ID 2119789-1
    ISSN 1542-7714 ; 1542-3565
    ISSN (online) 1542-7714
    ISSN 1542-3565
    DOI 10.1016/j.cgh.2024.02.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Biologics: how far can they go in Crohn's disease?

    Dunleavy, Katie A / Pardi, Darrell S

    Gastroenterology report

    2022  Volume 10, Page(s) goac049

    Abstract: Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic ... ...

    Abstract Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.
    Language English
    Publishing date 2022-09-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2710871-5
    ISSN 2052-0034
    ISSN 2052-0034
    DOI 10.1093/gastro/goac049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Resolution rates in clinical trials for microbiota restoration for recurrent

    Tariq, Raseen / Pardi, Darrell S / Khanna, Sahil

    Therapeutic advances in gastroenterology

    2023  Volume 16, Page(s) 17562848231174293

    Abstract: Background: Microbiota restoration is highly effective to treat recurrent : Objectives: To perform an updated meta-analysis to assess the efficacy of microbiota restoration for recurrent CDI in open-label registered prospective clinical trials ... ...

    Abstract Background: Microbiota restoration is highly effective to treat recurrent
    Objectives: To perform an updated meta-analysis to assess the efficacy of microbiota restoration for recurrent CDI in open-label registered prospective clinical trials compared to randomized controlled trials (RCTs).
    Design: A systematic review and meta-analysis was conducted.
    Data sources and methods: A systematic search of various databases was performed up to July 2022 to identify studies of interest. Clinical trials of microbiota restoration for recurrent CDI with clinical resolution with one dose were included. We calculated weighted pooled rates (WPRs) with 95% confidence intervals (CIs).
    Results: In all, 19 clinical trials with 1176 recurrent CDI patients were included. Of the patients treated with microbiota restoration, 897 experienced a clinical cure with a single microbiota restoration therapy (WPR, 78%; 95% CI, 71-85%). There was significant heterogeneity among studies with an
    Conclusions: Microbiota restoration in a randomized controlled setting leads to lower resolution rates compared to open label and observational settings, likely due to stricter definitions and inclusion criteria. Resolution rates in open-label studies were similar to observational studies.
    Language English
    Publishing date 2023-05-30
    Publishing country England
    Document type Journal Article
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848231174293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reply.

    Saha, Srishti / Pardi, Darrell S / Khanna, Sahil

    Gastroenterology

    2021  Volume 161, Issue 4, Page(s) 1345

    Language English
    Publishing date 2021-06-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2021.06.048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Effect of peripartum

    Saha, Srishti / Pardi, Ryan / Theiler, Regan N / Pardi, Darrell S / Khanna, Sahil

    Therapeutic advances in gastroenterology

    2023  Volume 16, Page(s) 17562848231170479

    Abstract: Background: The incidence of : Objective: To study the effect of peripartum CDI on pregnancy and neonatal outcomes.: Design: Retrospective cohort study.: Methods: Patients with peripartum CDI 12 weeks before pregnancy through 6 weeks postpartum ...

    Abstract Background: The incidence of
    Objective: To study the effect of peripartum CDI on pregnancy and neonatal outcomes.
    Design: Retrospective cohort study.
    Methods: Patients with peripartum CDI 12 weeks before pregnancy through 6 weeks postpartum (January 1996-February 2018) were matched with controls (peripartum women without CDI) 1:1 by age, year of delivery, and prior pregnancies. McNemar's test and conditional logistic regression were used to analyze the effect of CDI on pregnancy and neonatal outcomes (complications, mode of delivery).
    Results: Overall, 101 cases and 100 controls (1997-2018) were included; median age 27 (range, 20-41) years. Timing of CDI was as follows: pre-pregnancy: 15.8% (
    Conclusion: Peripartum CDI was associated with higher odds of cesarean delivery and lower odds of GBS infections. Larger studies exploring the effect of CDI on pregnancy and neonatal outcomes are needed.
    Language English
    Publishing date 2023-04-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848231170479
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection.

    Tariq, Raseen / Tosh, Pritish K / Pardi, Darrell S / Khanna, Sahil

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2023  Volume 42, Issue 8, Page(s) 1037–1041

    Abstract: We performed an updated study to investigate the rates of urinary tract infections (UTIs) in patients with recurrent Clostridioides difficile infection (CDI) who received fecal microbiota transplantation (FMT) for CDI. We found a significant reduction in ...

    Abstract We performed an updated study to investigate the rates of urinary tract infections (UTIs) in patients with recurrent Clostridioides difficile infection (CDI) who received fecal microbiota transplantation (FMT) for CDI. We found a significant reduction in number of UTIs after FMT compared to patients who received antibiotics for CDI treatment. After FMT, we also observed a trend towards reduction of antibiotic resistance in organisms causing UTI.
    MeSH term(s) Humans ; Fecal Microbiota Transplantation/adverse effects ; Clostridioides difficile ; Treatment Outcome ; Recurrence ; Clostridium Infections/microbiology ; Urinary Tract Infections/therapy ; Urinary Tract Infections/etiology
    Language English
    Publishing date 2023-06-23
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-023-04635-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Management of Acute and Chronic Pouchitis.

    Tome, June / Raffals, Laura E / Pardi, Darrell S

    Diseases of the colon and rectum

    2022  Volume 65, Issue S1, Page(s) S69–S76

    Abstract: Background: Restorative proctocolectomy with IPAA is the procedure of choice when colectomy is needed for medically refractory ulcerative colitis. Pouchitis is one of the most common complications among patients who have undergone IPAA and represents a ... ...

    Abstract Background: Restorative proctocolectomy with IPAA is the procedure of choice when colectomy is needed for medically refractory ulcerative colitis. Pouchitis is one of the most common complications among patients who have undergone IPAA and represents a spectrum of disease varying in both phenotype and clinical course.
    Objective: This study aimed to assist clinicians and surgeons in the treatment of both acute and chronic pouchitis, including newer therapies and future directions.
    Diagnosis and management: Diagnosis is made by endoscopy of the pouch with biopsy because other conditions may produce similar symptoms such as increased stool frequency, abdominal cramps, and urgency. Pouchitis is classified by duration (acute versus chronic), disease pattern (infrequent, relapsing, and continuous), and response to antibiotics (responsive, dependent, and refractory). The Pouchitis Disease Activity Index may be used to measure disease activity. The management of pouchitis is guided by the disease phenotype. Acute episodes are treated with an initial 2-week course of antibiotics (typically ciprofloxacin or metronidazole), although patients with relapsing or chronic pouchitis may require long-term antibiotic treatment or the cycling of different antibiotics. Certain probiotics may also be used for maintenance therapy in those with chronic symptoms. For patients with chronic antibiotic refractory pouchitis, oral budesonide, immunosuppressive agents (azathioprine), or biologic therapy (infliximab, adalimumab, vedolizumab, and ustekinumab) may be required for both induction and maintenance with close monitoring for potential side effects. In rare cases, diverting ileostomy or pouch excision may be required.
    Conclusion: Pouchitis represents a spectrum of disease phenotypes, ranging from acute antibiotic responsive pouchitis to chronic antibiotic refractory pouchitis. The management of pouchitis is primarily directed by the disease phenotype.
    MeSH term(s) Humans ; Pouchitis/diagnosis ; Pouchitis/etiology ; Pouchitis/therapy ; Proctocolectomy, Restorative/adverse effects ; Colitis, Ulcerative/complications ; Adalimumab/therapeutic use ; Anti-Bacterial Agents/therapeutic use
    Chemical Substances Adalimumab (FYS6T7F842) ; Anti-Bacterial Agents
    Language English
    Publishing date 2022-07-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 212581-x
    ISSN 1530-0358 ; 0012-3706
    ISSN (online) 1530-0358
    ISSN 0012-3706
    DOI 10.1097/DCR.0000000000002562
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: In Search of the (Clostridium difficile) Holy Grail.

    Pardi, Darrell S / Khanna, Sahil

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2019  Volume 70, Issue 6, Page(s) 1094–1095

    MeSH term(s) Biomarkers ; Clostridioides ; Clostridioides difficile ; Clostridium Infections/diagnosis ; Clostridium Infections/epidemiology ; Diarrhea ; Humans
    Chemical Substances Biomarkers
    Language English
    Publishing date 2019-05-17
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciz333
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: The natural history of histological changes in microscopic colitis.

    Sehgal, Kanika / Tome, June / Kamboj, Amrit K / Dierkhising, Ross A / Pardi, Darrell S / Khanna, Sahil

    Therapeutic advances in gastroenterology

    2023  Volume 16, Page(s) 17562848231168237

    Abstract: Background: Microscopic colitis (MC) causes chronic diarrhea. It has two histologic subtypes: lymphocytic colitis (LC) and collagenous colitis (CC). Little is known about the natural progression of disease with time and with treatment.: Objectives: ... ...

    Abstract Background: Microscopic colitis (MC) causes chronic diarrhea. It has two histologic subtypes: lymphocytic colitis (LC) and collagenous colitis (CC). Little is known about the natural progression of disease with time and with treatment.
    Objectives: We aimed to assess histological changes over time.
    Design: We designed a retrospective study including adults diagnosed with MC from January 1992 to January 2020 at Mayo Clinic.
    Methods: Pathology reports were reviewed until 31 October 2020. Histological assessments at least 8 weeks apart were considered as adequate follow-up. Histological change from one subtype to the other and resolution were tracked with univariate and multivariable Cox proportional hazards models.
    Results: Overall, 416 patients with a median age at diagnosis of 63.9 years with >1 histopathological assessment were identified. Histology at initial diagnosis was CC in 218 (52.4%) patients and LC in 198 (47.6%). No medications were associated with a histological change. However, histological resolution was more likely with the use of aspirin [hazard ratio (HR): 2.10, 95% confidence interval (CI): 1.34-3.31,
    Conclusion: Patients with LC have a higher chance of changing their histology as compared to CC. However, histological resolution was associated with the use of PPIs and aspirin, and treatment with budesonide.
    Language English
    Publishing date 2023-04-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848231168237
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top